Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on December 30, 2008
JNCI Journal of the National Cancer Institute 2009 101(1):8-10; doi:10.1093/jnci/djn482
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/1/8    most recent
djn482v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schmidt, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmidt, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

Urine Biomarkers May Someday Detect Even Distant Tumors

Charlie Schmidt

The first 150 words of the full text of this article appear below.

When it comes to sampling body fluids for cancer biomarkers, blood has traditionally been the dominant choice. That's not surprising—as a biofluid, blood offers favorable opportunities for clinical analysis: It mingles with proteins and other biomolecules involved in tumor growth, and because it flows through the entire body, it's exposed to every organ system. Moreover, the world's blood banks—a crucial resource for biomarker research—number in the thousands. With those advantages, most cancer biomarkers in routine use today come from blood, including the prostate-specific antigen (PSA) test, CA-125 for ovarian cancer, and HER2/neu for breast cancer.

But now another biofluid, urine, is making key inroads into the cancer biomarker realm. Urinary biomarkers reveal cancer not just in the organs of the urogenital tract (as might be expected) but also in more distant organs, such as the breast, ovaries, and brain. Evidence suggests that these new biomarkers, which include proteins, metabolites, and . . . [Full Text of this Article]

Using Biomarker Panels

Validation Concerns


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?